Kidney News and Research

RSS

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

Pros and cons of the estimated Glomerular Filtration Rate

As many as 26 million Americans live with chronic kidney disease (CKD) and according to the National Institutes of Health (NIH), at least 10.4 million (or 40%) don't even know they have it. Enter the estimated Glomerular Filtration Rate (eGFR), which has become the preferred method for identifying people with CKD.

23 Sep 2009

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

University of Michigan Health System researchers will lead a $10.25 million effort to study rare kidney diseases that cause kidney failure and the need for dialysis.

23 Sep 2009

$1.2 million grant to study centrosomes and cilia and their connections to human disease

If you don't know how a human cell is supposed to work, it's hard to offer a good explanation when the cell goes haywire -- as it does in cancer. That's why a Florida State University College of Medicine researcher has been awarded a $1.2 million grant to explore the role of centrosomes and cilia in cell division and development and their connections to human disease.

22 Sep 2009

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Three new HealthPartners Research Foundation studies will examine ways to prevent and treat childhood obesity and hypertension. One study will look at interventions to prevent obesity in children ages 5-9, another will focus on obesity prevention in children ages 2-5, while another will examine hypertension in children and adolescents, including the quality and cost of care.

21 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.

21 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Dialysis patient embarks on "Grandpa's Road Trip" with NxStage System One hemodialysis machine

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that home dialysis patient Harvey Wells, 57, has embarked on his third annual "Grandpa's Road Trip" with the NxStage(R) System One(TM). As a portable home hemodialysis machine, the NxStage System One provides Mr. Wells the opportunity to fit hemodialysis therapy into his own lifestyle and schedule. Mr. Wells is once again celebrating this freedom by traveling the country in his RV and sharing with other patients his experience doing home daily hemodialysis with the NxStage System One.

21 Sep 2009

Program to promote patients’ overall health following kidney transplant surgery

Patient adherence after a kidney transplant, or faithfully following a prescribed medical regimen, is vital to a transplant recipient's health and the survival of their new organ.

19 Sep 2009

Texas attemps to offer access to quality dialysis care

Local officials, physicians and patients in need of local dialysis care expressed encouragement over what appears to be a thawing of a certification logjam of dialysis facilities across the state of Texas, though remain concerned over 38 which still remain idling to many for more than a year – to the detriment of local jobs and patients in dire need of better access to quality dialysis care.

18 Sep 2009

Recipients of 2009 Norman S. Coplon Extramural Grants

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced the recipients of the 2009 Norman S. Coplon Extramural Grant Program.

18 Sep 2009

'Pathway to a Cure' walk event in California

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced their sponsorship of The Polycystic Kidney Disease Foundation's "Pathway to a Cure" walk event in California's capital of Sacramento.

18 Sep 2009

New vaccine may prove effective against urinary tract infections

University of Michigan scientists have made an important step toward what could become the first effective vaccine to prevent urinary tract infections, if the robust immunity achieved in mice can be reproduced in humans.

18 Sep 2009

Researchers to focus on abnormal fetal growth and chronic kidney disease

The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $3.5 million to study epigenetic changes - chemical modifications of genes caused by stress, diet or other environmental influences - and how they contribute to human diseases and biological processes.

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Mayo Clinic scientists conduct clinical study on functional dyspesia patients

"Nerve cells are found throughout the body, and just as their dysfunction in the brain can cause depression, we suspect overly sensitive nerves in the gut can produce this very uncomfortable indigestion," says Nicholas Talley, M.D., Ph.D., chair of the trial and chair of the Department of Internal Medicine at the Mayo Clinic campus in Florida.

18 Sep 2009

Vitamin K prevents age-related conditions

An important analysis conducted by Children's Hospital Oakland Research Institute scientists suggests the importance of ensuring optimal dietary intakes of vitamin K to prevent age-related conditions such as bone fragility, arterial and kidney calcification, cardiovascular disease, and possibly cancer. Vitamin K is concentrated in dark green plants such as spinach or Swiss chard, and is either not present or present in only small amounts in most multivitamin pills.

18 Sep 2009

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

Kidney News and Research

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Pros and cons of the estimated Glomerular Filtration Rate

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

$1.2 million grant to study centrosomes and cilia and their connections to human disease

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

Dialysis patient embarks on "Grandpa's Road Trip" with NxStage System One hemodialysis machine

Program to promote patients’ overall health following kidney transplant surgery

Texas attemps to offer access to quality dialysis care

Recipients of 2009 Norman S. Coplon Extramural Grants

'Pathway to a Cure' walk event in California

New vaccine may prove effective against urinary tract infections

Researchers to focus on abnormal fetal growth and chronic kidney disease

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

FDA approves Valturna tablets for treating high blood pressure

Mayo Clinic scientists conduct clinical study on functional dyspesia patients

Vitamin K prevents age-related conditions

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News